scholarly journals Treatment Effect of Donepezil is Greater in Moderate Stage Than in Mild Stage of Alzheimer’s Disease

2013 ◽  
Author(s):  
Jung
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Treatment Effect

scholarly journals Functional MRI technologies in the study of medication treatment effect on Alzheimer's disease

2018 ◽  
Vol 1 (1) ◽  
pp. 75-95 ◽  
Author(s):  
Hui Guo ◽  
Lukas Grajauskas ◽  
Baraa Habash ◽  
Ryan CN D'Arcy ◽  
Xiaowei Song
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Functional Mri ◽  
Treatment Effect ◽  
Medication Treatment

scholarly journals Risk Factors for Progression to Alzheimer's Disease in African Americans in a Large National Cohort

2020 ◽  
Author(s):  
Yejin Kim ◽  
Sean I Savitz ◽  
Jessica Lee ◽  
Paul E Schulz ◽  
Luyao Chen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
African Americans ◽  
Treatment Effect ◽  
Senile Dementia ◽  
P Value ◽  
Racial Groups ◽  
Diagnosis Codes ◽  
National Cohort

Objectives: To investigate risk factors for progression to Alzheimer's disease and related dementias (ADRD) in African Americans and non-Hispanic Caucasians in a large US cohort. Design: A matched case-control design using electronic health records (EHRs) from 2000 - 2017. Setting: Cerner EHRs database covering more than 600 Cerner client hospitals. Participants: 79,120 patients aged 65 and older (#ADRD=39,560, #non ADRD older adults=39,560) from an initial cohort of 49,826,000 patients. Measurements: We converted ICD9 or ICD10 diagnosis codes into PheWas codes to increase clinical relevance. Then we detected ADRD as having both ADRD diagnosis codes and medications. We considered PheWas codes for Alzheimer's disease, dementia with cerebral degenerations, senile dementia, and vascular dementia. We considered ADRD medications including acetylcholine and memantine. Results: Using two-step propensity score matching, we built an African American cohort of 4,429 and a 4,570-person matched Caucasian cohort that was similar in terms of onset age, observation length, sex, and known ADRD risks (diabetes, vascular disease, heart disease, head injury, and obesity). Older African Americans had a statistically significant progression from cerebrovascular risk (transient ischemic attack) to ADRD incidence (treatment effect coefficient = 0.0978, p-value <0.000) whereas the matched Caucasians did not (treatment effect coefficient = 0.403, p-value = 0.196). Conclusion: Our extensive causal analysis using a nationwide EHR discovered disease progression pathways to ADRD. The carefully matched cohorts from different racial groups showed different progression, which partly explains the racial disparities in ADRD incidence.

scholarly journals AUTHORS RESPONSE TO UMBRICHT D, LETTER TO THE EDITOR REFERRING FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS. THE JOURNAL OF PREVENTION OF ALZHEIMER’S DISEASE, 2020

2020 ◽  
pp. 1-1
Author(s):  
P.S. Aisen ◽  
R. Raman
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Treatment Effect ◽  
Phase 3 ◽  
Letter To The Editor ◽  
Full Analysis ◽  
Risky Business

Dr. Umbricht suggests that the two examples we cite in our viewpoint (1) support rather than call into question the value of interim futility analyses in Alzheimer’s disease (AD) trials. He points out that the first example, the Phase 3 trials of aducanumab, the futility analyses did indeed indicate a trend toward a beneficial treatment effect in one of the two trials though the planned pooled futility decision led to stopping the trials. In the second case, in which a futility analysis led to a halt, full analysis of available data suggested efficacy; a subsequent study was negative.

scholarly journals P2-109: CSF CHOLINERGIC INDEX, A NEW BIOMEASURE OF TREATMENT EFFECT IN PATIENTS WITH ALZHEIMER'S DISEASE

2019 ◽  
Vol 15 ◽  
pp. P614-P614
Author(s):  
Azadeh Karami ◽  
Maria Eriksdotter ◽  
Ahmadul Kadir ◽  
Ove Almkvist ◽  
Agneta K. Nordberg ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Treatment Effect

Non-Steroidal Anti-Inflammatory Drugs as a Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Treatment Effect

Drugs & Aging ◽  
2015 ◽  
Vol 32 (2) ◽  
pp. 139-147 ◽  
Author(s):  
Marina Miguel-Álvarez ◽  
Alejandro Santos-Lozano ◽  
Fabian Sanchis-Gomar ◽  
Carmen Fiuza-Luces ◽  
Helios Pareja-Galeano ◽  
...  
Keyword(s):  
Systematic Review ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Treatment Effect ◽  
Meta Analysis ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

scholarly journals Targeted screening for Alzheimer’s disease clinical trials using data-driven disease progression models

2021 ◽  
Author(s):  
Neil P. Oxtoby ◽  
Cameron Shand ◽  
David M. Cash ◽  
Daniel C. Alexander ◽  
Frederik Barkhof ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Cognitive Impairment ◽  
Disease Progression ◽  
Treatment Effect ◽  
Screening Tool ◽  
Data Driven ◽  
Full Cohort ◽  
Computational Screening

ABSTRACTHeterogeneity in Alzheimer’s disease progression contributes to the ongoing failure to demonstrate efficacy of putative disease-modifying therapeutics that have been trialled over the past two decades. Any treatment effect present in a subgroup of trial participants (responders) can be diluted by non-responders who ideally should have been screened out of the trial. How to identify (screen-in) the most likely potential responders is an important question that is still without an answer. Here we pilot a computational screening tool that leverages recent advances in data-driven disease progression modelling to improve stratification. This aims to increase the sensitivity to treatment effect by screening out non-responders, which will ultimately reduce the size, duration, and cost of a clinical trial. We demonstrate the concept of such a computational screening tool by retrospectively analysing a completed double-blind clinical trial of donepezil in people with amnestic mild cognitive impairment (clinicaltrials.gov: NCT00000173), identifying a data-driven subgroup having more severe cognitive impairment who showed clearer treatment response than observed for the full cohort.

How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy

2020 ◽  
Vol 17 ◽  
Author(s):  
Hankyung Jun ◽  
Sang Kyu Cho ◽  
Elmar R. Aliyev ◽  
Soeren Mattke ◽  
Sze-Chuan Suen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cost Effectiveness ◽  
Treatment Effect ◽  
Effect Size ◽  
Cost Effective ◽  
High Price ◽  
Disease Modifying Therapy ◽  
Treatment Effect Size ◽  
Disease Modifying

Background:: Recent trials suggest that disease-modifying therapy (DMT) for Alzheimer’s disease may become available soon. With the expected high price and a large patient pool, the budget impact will be substantial. Objective: We explore combinations of effectiveness and price under which a DMT is cost-effective. Method: We used an open-source model to conduct two-way scenario analyses for both payer and societal perspectives, varying price, and treatment effect size simultaneously. The analysis generates cost-effectiveness threshold prices over a potential range of DMT effectiveness in patients aged 65+ with mild cognitive impairment due to Alzheimer’s disease in the US. Results: Under the willingness-to-pay a threshold of $150,000 per quality-adjusted life year and assuming 30% risk reduction relative to the standard of care, the maximum cost-effective price of a DMT per patient per year is ~$22,000 and ~$15,000 from societal and payer perspectives, respectively. Conclusion: Joint variation of price and treatment effect size can help assess the cost-effectiveness of a potential Alzheimer’s disease treatment.

Sign in / Sign up

Export Citation Format

Share Document